Follow-On Biologics: White House Calls 7 Years Of Exclusivity A "Generous Compromise"
This article was originally published in The Pink Sheet Daily
Reply to Rep. Waxman notes that "a serious review of FDA's existing authorities is underway."
You may also be interested in...
FDA should start approving follow-on biologics even in the absence of legislation, House committee chairman tells president in bid to increase his negotiating leverage.
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
Yes, Gottlieb’s in there twice; things get complicated when an agency starts to lose credibility.